We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis

By LabMedica International staff writers
Posted on 18 Jul 2026

Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity to trigger reactions. More...

Functional assays can be informative yet often rely on viable cells and specialized procedures that limit routine use. Safer, mechanism-based tests that align with oral food challenge outcomes are needed to guide patient management. 

Hiroshima University, together with Aichi Children’s Health and Medical Center and Shimane University, developed an improved allergen-specific IgE (sIgE) test derived from the AlphaCL method. Originally created to detect serum antibody cross-linking in patients with hives, AlphaCL was adapted to assess whether a patient’s IgE can trigger effector mechanisms relevant to allergic reactions. The modified approach evaluates allergen-induced cross-linking of IgE receptors (FcεRI) without using living cells.

The investigators addressed a key limitation of the conventional AlphaCL assay by reducing interference from blood serum components that can obscure detection. Using modified allergens, the method facilitates removal of interfering serum constituents, allowing these components to be washed off the reaction plate before readout. In doing so, the assay measures not only the amount of IgE present but the fraction that is functionally capable of inducing allergic responses.

Performance was evaluated by comparing the improved and conventional AlphaCL assays under serum-containing conditions known to interfere with IgE detection. The modified method retained 66% of its signal observed in serum-free samples, whereas the conventional method retained 3.3%, indicating substantially stronger signal preservation. In patient testing with representative food allergens—egg, wheat, and milk—the improved assay detected allergen-sIgE in 93.3% (28 of 30) of individuals who were positive on oral food challenges, and findings suggest the approach can be adapted to a wide range of allergen targets.

The study appears in Methods (2026). The authors note that analyses included only patients with positive oral food challenge results and a limited number of cases, underscoring the need for further evaluation.

“In order for allergic reactions to occur, IgE antibodies must bind to IgE receptors (FcεRI) on effector cells such as mast cells, and cross-linking of multiple FcεRI molecules by allergens is required to trigger the response. Consequently, conventional tests may classify individuals as having food allergies … when allergen-specific IgE is present but does not lead to actual symptom development. This discrepancy between test results and clinical symptoms represents a major challenge, contributing to diagnostic uncertainty and unnecessary dietary restrictions,” said Yuki Koga, a pharmacist in the Department of Pharmaceutical Services at Hiroshima University Hospital and the primary author of the research paper.

“[Our modified] AlphaCL method allows assessment of allergen-induced FcεRI cross-linking without the use of cells. In other words, it enables evaluation not only of how much IgE is present but also of how much functionally active IgE capable of inducing allergic reactions is present, using a simple and reproducible system. This study demonstrates the feasibility of detecting functional, [allergy-inducing] IgE through a more practical and accessible approach, highlighting the methodological significance of this technique,” added Koga.

Related Links
Hiroshima University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.